Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib

被引：0
|
作者：
Duan, J. C. [1 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
NSCLC; Third Generation EGFR-TKI; Resistance Mechanism;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-29
引用
下载
收藏
页码：S652 / S652
页数：1
相关论文
共 50 条
  • [1] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
    Zhang, H.
    Cun, F. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
  • [2] Study of First-Line Aumolertinib Plus Bevacizumab and Pemetrexed Treated NSCLC with EGFR Mutation and Brain Metastasis
    Fu, S.
    Liu, J.
    Fu, P.
    Li, H.
    Yang, X.
    Xie, C.
    Zhang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S414 - S415
  • [3] Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
    Fang, S.
    Xu, T.
    Liu, N.
    Wang, X. Y.
    Cheng, W. W.
    Fang, H. H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S650 - S650
  • [4] High-dose Aumolertinib as First-line Treatment in Patients With Brain Metastases Associated With EGFR Mutated NSCLC
    Fan, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S422 - S422
  • [5] Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?
    Yang, James Chih-Hsin
    LANCET ONCOLOGY, 2019, 20 (05): : 602 - 603
  • [6] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation positive locally advanced or metastatic non-small cell lung cancer (NSCLC): A randomized multicenter study
    Hu, Y.
    Zhang, F.
    Zhao, M.
    Zheng, Z.
    Zhang, H.
    Jiang, T.
    Liu, Z.
    Wen, J.
    Gan, X.
    Wang, H.
    Wu, L.
    Cang, S.
    Zhao, J.
    Li, X.
    Peng, L.
    Fan, Z.
    Shen, G.
    Zhou, Q.
    Zou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1312 - S1312
  • [7] Aumolertinib plus apatinib versus aumolertinib as first-line treatment in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Zhang, Fan
    Hu, Yi
    Han, Xiao
    Hu, ZhiSong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR plus NSCLC Patients: The Updated Results
    Fang, S.
    Xu, T.
    Zhao, X.
    Liu, N.
    Wang, X.
    Cheng, W.
    Fang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S671 - S671
  • [9] Concurrent Aumolertinib Plus Icotinib for First-Line Treatment of EGFR-Mutant NSCLC with CNS Metastases: A Prospective Phase I/II Study
    Huang, M. J.
    Yu, M.
    Gong, Y. L.
    Li, Y. Y.
    Liu, Y. M.
    Peng, F.
    Yu, Y.
    Xiu, W. G.
    Wang, Y. S.
    Zou, B. W.
    Fan, H.
    Zhong, L. Q.
    Liu, T. Q.
    Wang, X. F.
    Xu, Y.
    Zhou, L.
    Lu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S146 - S146
  • [10] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
12345